GRI Bio Announces Closing of $8.0 Million Public Offering
GRI Bio, Inc. (GRI)
Company Research
Source: GlobeNewswire
LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof), Series F warrants to purchase up to 10,666,667 shares of common stock (the "Series F Warrants"), at a combined public offering price of $0.75 per share (or per common stock equivalent in lieu thereof) and accompanying Series F Warrant. The Series F Warrants have an exercise price of $0.75 per share and are exercisable immediately upon issuance and will expire on the fifth anniversary of the initial issuance date. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company fro
Show less
Read more
Impact Snapshot
Event Time:
GRI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRI alerts
High impacting GRI Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GRI
News
- GRI Bio Announces Pricing of $8,000,000 Million Public OfferingGlobeNewswire
- GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) GlobeNewswire
- GRI Bio (NASDAQ:GRI) had its price target raised by analysts at Ascendiant Capital Markets from $35.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- GRI Bio (NASDAQ:GRI) had its price target raised by analysts at Ascendiant Capital Markets from $34.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
GRI
Sec Filings
- 12/12/25 - Form 8-K
- 12/12/25 - Form 424B4
- 12/12/25 - Form 8-K
- GRI's page on the SEC website